4.8 Article

Sequence analysis of mutations and translocations across breast cancer subtypes

期刊

NATURE
卷 486, 期 7403, 页码 405-409

出版社

NATURE PORTFOLIO
DOI: 10.1038/nature11154

关键词

-

资金

  1. Carlos Slim Health Institute in Mexico
  2. CancerCare Manitoba
  3. University of Manitoba
  4. John Gavin Post-doctoral Fellowship
  5. Genesis Oncology Trust of New Zealand
  6. Mexican Council of Science and Technology (CONACyT)
  7. NIH [CA122099]
  8. Dana-Farber/Harvard SPORE in breast cancer under NCI grant [CA089393]

向作者/读者索取更多资源

Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with an estimated 1.38 million new cases and 458,000 deaths in 2008 alone(1). This malignancy represents a heterogeneous group of tumours with characteristic molecular features, prognosis and responses to available therapy(2-4). Recurrent somatic alterations in breast cancer have been described, including mutations and copy number alterations, notably ERBB2 amplifications, the first successful therapy target defined by a genomic aberration(5). Previous DNA sequencing studies of breast cancer genomes have revealed additional candidate mutations and gene rearrangements(6-10). Here we report the whole-exome sequences of DNA from 103 human breast cancers of diverse subtypes from patients in Mexico and Vietnam compared to matched-normal DNA, together with whole-genome sequences of 22 breast cancer/normal pairs. Beyond confirming recurrent somatic mutations in PIK3CA(11), TP53(6), AKT1(12), GATA3(13) and MAP3K1(10), we discovered recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. Furthermore, we have identified a recurrent MAGI3-AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression. The MAGI3-AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据